These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 30797042)
1. A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment. Gordon MS; Vocci FJ; Taxman F; Fishman M; Sharma B; Blue TR; O'Grady KE Contemp Clin Trials; 2019 Apr; 79():21-27. PubMed ID: 30797042 [TBL] [Abstract][Full Text] [Related]
2. Buprenorphine Treatment for Probationers and Parolees. Gordon MS; Kinlock TW; Schwartz RP; Couvillion KA; Sudec LJ; O'Grady KE; Vocci FJ; Shabazz H Subst Abus; 2015; 36(2):217-25. PubMed ID: 24701967 [TBL] [Abstract][Full Text] [Related]
3. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial. Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660 [TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for opioid addiction in community corrections. Schwartz RP; Mitchell MM; O'Grady KE; Kelly SM; Gryczynski J; Mitchell SG; Gordon MS; Jaffe JH Int Rev Psychiatry; 2018 Oct; 30(5):117-135. PubMed ID: 30522370 [TBL] [Abstract][Full Text] [Related]
5. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726 [TBL] [Abstract][Full Text] [Related]
6. Buprenorphine Treatment for Opioid Use Disorder: An Overview. Shulman M; Wai JM; Nunes EV CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259 [TBL] [Abstract][Full Text] [Related]
7. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256 [TBL] [Abstract][Full Text] [Related]
8. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068 [TBL] [Abstract][Full Text] [Related]
9. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100 [TBL] [Abstract][Full Text] [Related]
10. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265 [TBL] [Abstract][Full Text] [Related]
11. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial. Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760 [TBL] [Abstract][Full Text] [Related]
12. Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation. Belden C; Kopak A; Coules C; Friesen T; Hall J; Shukla S J Subst Use Addict Treat; 2024 Jul; 162():209364. PubMed ID: 38626851 [TBL] [Abstract][Full Text] [Related]
13. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation. Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131 [TBL] [Abstract][Full Text] [Related]
15. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision. Kennedy-Hendricks A; Bandara S; Merritt S; Barry CL; Saloner B Drug Alcohol Depend; 2021 Sep; 226():108881. PubMed ID: 34218008 [TBL] [Abstract][Full Text] [Related]
16. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder. Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790 [TBL] [Abstract][Full Text] [Related]
17. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. Nunes EV; Scodes JM; Pavlicova M; Lee JD; Novo P; Campbell ANC; Rotrosen J Am J Psychiatry; 2021 Jul; 178(7):660-671. PubMed ID: 34170188 [TBL] [Abstract][Full Text] [Related]
18. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688 [TBL] [Abstract][Full Text] [Related]
19. Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Shulman M; Provost S; Ohrtman K; Novo P; Meyers-Ohki S; Van Veldhuisen P; Oden N; Otterstatter M; Bailey GL; Liu D; Rotrosen J; Nunes EV; Weiss RD Contemp Clin Trials; 2024 Jul; 142():107543. PubMed ID: 38657730 [TBL] [Abstract][Full Text] [Related]
20. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]